Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Zimmer Biomet Holdings, Inc. Chairman, President and CEO Ivan Tornos reported equity award and related share movements. He acquired 15,996 shares of common stock through the exercise of restricted stock units and received a new grant of 65,103 restricted stock units, each representing one future share of common stock.
To cover tax withholding on the RSU vesting, 8,846 common shares were withheld by the company at a price of $98.62 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Tornos directly owned 59,149 shares of common stock, which include 246 shares acquired under the Employee Stock Purchase Plan, and 65,103 restricted stock units that vest in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings, Inc. executive vice president and CFO Suketu Upadhyay reported equity compensation activity involving restricted stock units (RSUs) and common stock. He received a grant of 21,701 RSUs, each representing a contingent right to one share of Zimmer Biomet common stock, vesting annually over three years in one-third increments starting February 20, 2027.
On the same date, 5,445 RSUs were converted into 5,445 shares of common stock through an exercise or conversion transaction. Of those shares, 2,446 were withheld by the company at a price of $98.62 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, Upadhyay directly owned 57,753 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an equity compensation award tied to past performance. She acquired 3,935 performance-based restricted stock units, each representing one share of common stock, following a determination on February 19, 2026 of results for the 2023–2025 performance period. These 3,935 RSUs will vest on March 6, 2026, subject to the award’s terms.
Zimmer Biomet Holdings reported that Group President, EMEA, Wilfred Van Zuilen acquired 4,843 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock. These RSUs were earned based on performance for the 2023–2025 period, as determined on February 19, 2026, and are scheduled to vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. executive vice president and CFO Suketu Upadhyay reported an acquisition of 10,217 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock at no purchase price.
The RSUs were originally granted as performance-based awards on March 6, 2023, with results tied to a performance period covering 2023 to 2025. Based on actual performance determined on February 19, 2026, 10,217 RSUs were earned and are scheduled to vest on March 6, 2026, if vesting conditions are satisfied.
ZIMMER BIOMET HOLDINGS, INC. reported that executive Paul A. Stellato, its VP, Controller and Chief Accounting Officer, acquired 1,363 restricted stock units as part of a performance-based equity award. These RSUs were earned based on performance for the 2023–2025 period and are scheduled to vest on March 6, 2026.
Zimmer Biomet Holdings senior vice president and chief legal officer Chad F. Phipps reported an equity award tied to past performance. He acquired 4,692 restricted stock units as of February 19, 2026, at a stated price of $0.00 per unit. These RSUs were earned under a performance-based grant covering the 2023–2025 period and are scheduled to vest on March 6, 2026. Each RSU represents the right to receive one share of Zimmer Biomet common stock.
Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit. These RSUs were earned from performance-based awards granted in March and September 2023 for the 2023–2025 performance period.
Based on actual performance determined on February 19, 2026, Yi Sang earned 5,298 RSUs from the March 2023 grant and 1,752 RSUs from the September 2023 grant. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and the 7,050 RSUs will vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. Chairman, President and CEO Ivan Tornos reported an acquisition of 24,436 restricted stock units (RSUs) tied to prior performance-based awards. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock at no purchase price.
The RSUs relate to performance-based grants awarded in March and September 2023 for a 2023–2025 performance period. Based on actual performance determined on February 19, 2026, he earned 12,184 RSUs from the March grant and 12,252 RSUs from the September grant, which together will vest on March 6, 2026 if conditions are satisfied.
Zimmer Biomet Holdings, Inc. files its annual report describing a global orthopedic and musculoskeletal business built around knees, hips, S.E.T. (sports medicine, extremities, trauma, CMFT) and a growing digital and robotic ZBEdge platform. The company sells mainly through consignment, which represented about 85% of 2025 net sales, with no single customer over 2%.
Operations are organized into Americas, EMEA and Asia Pacific, with the U.S. dominating Americas and Japan leading Asia Pacific. As of February 10, 2026, there were 195,652,004 common shares outstanding, and non‑affiliate share value was about $18.0 billion as of June 30, 2025.
Zimmer Biomet highlights extensive R&D with roughly 2,000 employees, heavy regulation from FDA, EU MDR and other regimes, and growing scrutiny on data privacy, cybersecurity and AI. The report details risks around competition, pricing pressure, restructuring, product portfolio rationalization, supply chain, ERP implementation issues, cyber attacks, high leverage of about $7.5 billion of debt, tax changes and global macro uncertainty.